Protein-protein interactions are ubiquitous in all organisms and are vital points where intervention for therapeutic purposes can be targeted (1,2). One method is to take the 88
traditional route of drug design, and develop small molecules based on virtual and/or real screening. This route has the strength and weaknesses of currently used drug design methodology. Another possible method is to design peptides that mimic the structure of a part of the protein that forms the interface. This strategy is particularly tempting where the binding portion forms a regular secondary structure.
The helix is an important structural element, which has been widely used in nature in protein-protein and protein-nucleic acid interactions. It would thus be desirable to have a general strategy to produce a helical peptide mimic. We wanted to create a general peptide backbone, which is helical and protease resistant, onto which functional groups could be grafted with relative synthetic ease, without changing the overall conformational properties.
Among readily available natural and non-natural amino acids, a-amino isobutyric acid (Aib) is an established alanine analog known to strongly favor helical conformations (3) (4) (5) (6) .
Owing to its strong helical preference for the backbone Ramachandran angles, it has been shown to produce helical conformations regardless of other amino acid types present in the peptide. It can also be easily incorporated in standard peptide synthesis protocols (7) .
In addition, Aib has the added advantage from the viewpoint of the conformational entropy change that accompanies binding. Since the allowed conformational space for Aib residue is restricted, upon binding, the conformational entropy loss of the Aib residue is expected to be less than the mono-alkylated amino acids that it substitutes (8) . Thus, Aib residues should also improve the binding affinity by reducing the loss of conformational entropy upon binding. Finally, since Aib does not belong to the standard amino acid repertoire, peptides containing Aib may be more protease resistant (9) , thus overcoming one of the common problems of peptide based drugs, namely, poor stability in vivo.
As a test case, we chose the p53-hdm2 interaction (10).
p53 is a multidomain protein, which lies at the center of the response to genotoxic stress (11, 12) . It is an important regulator of cell cycle progression that responds to DNA damage and repair. The N-terminal domain 1-42 is responsible for trans-activation function and binding with Hdm2, which downregulates the levels of p53 in the normal cell. In some tumor cells, Hdm2 is overexpressed resulting in the inhibition of wild-type p53 present. Thus, inhibition of p53-Hdm2 interaction may be an important intervention strategy for these types of tumor. Although the NMR structural study of the N-terminal domain of p53 has shown to be disordered, with little structure (13), the crystal structure of a 15-mer N-terminal part of p53-derived peptide (residues 15-29, of which residues 17-29 are ordered in crystal), bound to Hdm2, shows the p53 interaction region to be helical (14) . Three residues on one face of the helix, Phe19, Trp23 and Leu26, participate in binding interactions along with some hydrogen bonds. 
Experimental Procedures

Peptide design
In order to design a minimalist version of p53 that would retain its binding capacity to Hdm2, possibly with a higher affinity constant, we started with the sequence and the distance. In designing a p53 mimic, we preserved these Banerjee et al . Aib-based backbone as scaffolds for helical peptide mimics five residues. In addition, Thr2 was preserved since the N-cap position of a helix is often involved in imparting helix stability through capping interactions (15) and Thr2 was found to initiate the helix by H-bond interactions with Asp5. All other residues, except Glu1 and Glu12, were substituted by Aib for its proven ability to promote helix formation in short peptides. All peptides were acetylated at the N-termini because it is known to favor helical conformation when present at the N-cap position (16) .
Residue numbering of the peptides used through out this work is given Fig. 1 (Trp23 of human p53 corresponds to Trp7 in our peptides).
Peptide synthesis and characterization
The peptides were synthesized on a Fmoc-Glu (v : v) with TSP (3-(trimethylsilylpropionic2,2,3,3,d4 acid, sodium salt)) as the internal standard. Water suppression was achieved by using WATERGATE pulse sequence (17) for all experiments. TOCSY (18) and NOESY (19) experiments were performed using standard protocol (20) . For structural calculations of Ep53, the aN and NN NOE (Nuclear Ovehaues Effect) crosspeaks were translated into suitable distance upper limits (weak, 3.5 Å ; medium, 3.0 Å ; strong, 2.5 Å ). In addition, the backbone dihedral angles of the Aib residues were restricted (w5-65u15;
y 5-25u15). Using these as inputs, 100 structures were generated using the simulated annealing protocol DYANA (21) . Based on pairwise rmsd of the structures (residues 4-11
were compared since there were no NMR constraints at the N-termini), a cluster analysis yielded families of conformations, discussed later.
Hdm2 purification and inhibition assay
The recombinant p53 and GST-hdm2 (1-188), proteins were purified as described earlier (22) . The peptides were dissolved in DMSO (dimethyl sulfoxide) and the concentra- The intensity of aN (i, i+1) cross-peaks in Ep53 were comparable or slightly greater than that of Na (i, i) crosspeaks (for Trp7 the Na (i, i) cross-peak was more intense than the aN (i, i+1) cross-peak). For a helical backbone, the aN (i, i+1) cross-peaks would have been comparable (or weaker), and for a disordered backbone, the aN (i, i+1) cross-peaks would have been stronger than the Na (i, i) cross-peaks (27) . Therefore, unlike Np53, Ep53 can be considered to be in a partial helical conformation in solution.
There were no nonsequential cross-peaks in the Na region except for a peak between Asp5 C a H and a ring proton of Trp7. Several NN (i, i + 1) cross-peaks were observed: weak (4/5, 8/9 and 10/11), medium (7/8) and strong (6/7). Figure 4 shows several superposed backbone structures of Ep53 derived from NOE distance constraints. The C-terminal portion of the peptide is largely ordered and helical whereas the residues in the N-terminus are more ill-defined with little NOE constraints. Figure 4 also shows the hdm2-bound conformation of p53 (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) peptide (14), which is largely helical. The helical part of the Ep53 peptide is similar to the receptor-bound structure, whereas the N-terminal part is disordered.
Protease resistance
One of the major problems with peptide-based therapeutic strategies is that they often have a very low biological half-life. In many cases, this is because of initial proteolysis. Inhibition by the hdm2-binding peptides
The inhibitory activities of Ep53 and Np53 peptides were evaluated in the ELISA hdm2 (22) and their IC 50 was determined ( Table 1 ). The Ep53 peptide inhibited the p53-hdm2 interaction (IC 50 55.2 mm) more efficiently than 
Conclusion
The peptide Ep53 is partly in helical conformation and binds to the receptor with increased affinity (compared with Np53) even though the N-terminal portion is still disordered at 258C. More importantly, the peptide is highly resistant to protease cleavage. In a previous study, it was
shown that an octameric peptide, with suitably modified side-chains, could bind to hdm2 with nanomolar affinity (29) . Clearly, these side-chains can be grafted on to an Aib-based peptide backbone similar to the ones described in this article to produce highly protease-resistant, soluble peptide mimics which can bind to the receptor with more enhanced binding. Thus, for helical peptides, Aib-based design of peptide mimics appears to be a feasible method for producing lead compounds. Prior to appropriate alteration of the side-chains we are currently designing a peptide that optimizes the placement of Aib residues in Ep53 such that a helical conformation is obtained in isolation along with an enhanced value of IC 50 .
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